- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC
EP: 2.Strategies to Increase Biomarker Testing Rates
EP: 3.Limitations on Optimal Biomarker Testing Rates
EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes
EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC
EP: 6.NCCN Recommendations by PD-L1 Expression Level
EP: 7.Limitations of NCCN PD-L1 Expression Recommendations
EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC
EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC
EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response
EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection
EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
Video content above is prompted by the following:
- Looking ahead, what is the most critical priority to meaningfully enhance outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations?
AI in Oncology: Opportunities and Challenges for NSCLC
January 1st 2025Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.
Read More
Precision Oncology in NSCLC: Overcoming Patient Selection Barriers
December 23rd 2024Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.
Read More
Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC
December 19th 2024The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.
Read More
